We are live on ! Find out more
OYST

Oyster Point Pharma, Inc. Common Stock

Delisted

OYST was delisted on the 30th of December, 2022.

72 hedge funds and large institutions have $520M invested in Oyster Point Pharma, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 25 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,450% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 2

257% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 7

67% more funds holding

Funds holding: 4372 (+29)

12% more capital invested

Capital invested by funds: $464M → $520M (+$55.1M)

9.35% more ownership

Funds ownership: 62.26%71.61% (+9.4%)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

Holders
72
Holders Change
+29
Holders Change %
+67.44%
% of All Funds
1.47%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
31
Increased
25
Reduced
7
Closed
2
Calls
Puts
Net Calls
Net Calls Change

OYST Hedge Fund Activity: Q2 2020 in Review

72 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q2 2020, worth a combined $520M — up 12% from $464M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new OYST positions and 2 closed out — a net gain of 29 holders — while 25 added to existing stakes and 7 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $40.3M. The largest seller was Board of Trustees of The Leland Stanford Junior University, cutting an estimated $1.39M.

  • 72 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q2 2020, up from 43 in Q1 2020.
  • Funds reported $520M of Oyster Point Pharma, Inc. Common Stock stock for Q2 2020, up 12% quarter-over-quarter.
  • 31 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q2 2020 and 2 closed out, a net change of +29 holders.
  • The largest Oyster Point Pharma, Inc. Common Stock buyer in Q2 2020 was Wellington Management Group, an estimated $40.3M added.
  • The largest Oyster Point Pharma, Inc. Common Stock seller in Q2 2020 was Board of Trustees of The Leland Stanford Junior University, an estimated $1.39M sold.

Based on aggregated 13F filings for Q2 2020.